EP Patent

EP1843771B1 — Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity

Assigned to Novartis Pharma GmbH Austria · Expires 2011-09-21 · 15y expired

What this patent protects

The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, especially for the curative and/or prophylactic treatment of leukemia…

USPTO Abstract

The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, especially for the curative and/or prophylactic treatment of leukemia, myelodysplastic syndromes or pulmonary hypertension, and to a method of treating diseases that respond to modulation of kinase activity, especially tie-2 kinase activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1843771B1
Jurisdiction
EP
Classification
—
Expires
2011-09-21
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Pharma GmbH Austria
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.